SBIR Phase I: Expressing bacterial luciferase in zebrafish as an innovative new tool for data-intensive, higher-throughput drug discovery
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- 490 BIOTECH INC
- Proposal award date
- 2014-01-01
- Contract end date
- 2014-12-31
- UEI
- L2T9XGZ1JUL5
- Solicitation number
- Not reported
- Topic code
- BC
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs
- Autonomously-activating bioluminescent reporters to enable continuous, real-time, non-invasive brain cell imaging
- Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows
- Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine
- Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs
Research funding history
11 SBIR/STTR records share this UEI (2013–2019). Reported award amounts total $5,038,908. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Agriculture